Muhammad M. Nashatizadeh, M.D.

Professional Background

Muhammad Mahdi Nashatizadeh, M.D., was born and raised in Emporia, Kansas, and completed his undergraduate degree in 1998 with highest honors as a University Scholar at Emporia State University, where he majored in biology and minored in chemistry. He completed his medical degree at the University of Kansas School of Medicine in Kansas City in 2003.

He completed his internship in internal medicine at the University of Kansas School of Medicine in Wichita in 2004 before returning to Kansas City to complete his neurology residency in 2007. After serving as chief resident during 2006-2007, he pursued additional movement disorder fellowship training at Baylor College of Medicine in Houston, Texas, then returned to Kansas in 2008. He is board certified in neurology by the American Board of Psychiatry and Neurology (ABPN).

Known as "Dr. Muhammad" by numerous patients over the years, his academic career was postponed for seven years as he worked as a neurohospitalist at a community hospital and evaluated people with either movement and/or cognitive disorders in his outpatient clinic. He returned to the University of Kansas School of Medicine as faculty in the Department of Neurology in November 2015.

He has served as the director of Inpatient Movement Disorders since 2017. He is the primary attending covering the inpatient academic neurology consultation service. In this role, he works with emergency medicine, internal medicine, rehabilitation and surgery services to assess and address the neurological issues affecting hospitalized patients. He also educates geriatrics fellows; residents from neurology, internal medicine and psychiatry; and medical students. His teaching emphasizes understanding how systemic medical disease can affect patients neurologically and recognizing and identifying how multiple layers of neurological illness affect hospitalized patients.

For these efforts, he was selected as a top five finalist for the prestigious Rainbow Award in 2018-2019. He has also been voted the Neurology Attending Educator of the Year (Student Voice Award) by third-year medical students during the years of 2017-2021.

• BS, Biology with Honors as a University Scholar, Emporia State University
• MD, medicine, University of Kansas School of Medicine
• Other, University of Kansas School of Medicine
• Other, Neurology, University of Kansas School of Medicine
• Other, Neurology, University of Kansas School of Medicine
• Other, Baylor College of Medicine

• Class C (highest certification), Expanded Disability Status Scale
• Kansas Medical License, Kansas Board of Healing Arts
• Missouri Medical License, Missouri Board of Healing Arts
• Neurology, American Board of Psychiatry and Neurology

• Kansas City Clinical Neuroscience Society, Member, 2016 - Present
• Movement Disorder Society, Member, 2006 - Present
• American Academy of Neurology, Member, 2004 - Present

---

Research

Overview

Although he no longer sees clinic patients, his career research objectives include developing greater understanding of why people develop atypical parkinsonism and parkinson-plus syndromes, studying the overlapping features of movement disorders with cognitive decline and sensory disturbance, and identifying new treatment options for debilitating movement disorders.

• Nashatizadeh, MM, Jankovic, J. 2008. Treatment of freezing of gait in Parkinson's disease with deep brain stimulation of the pedunculopontine nucleus. Neurology, 70 (Suppl 1), A388-389
• Nashatizadeh, MM, Jankovic, J. 2008. Deep brain stimulation for peripherally-induced parkinsonism. Movement Disorders, 23 (Suppl 1), S135
• Nashatizadeh, MM, Jimenez, JE, Davidson, AL, Jankovic, J. 2008. A randomized, double-blind, placebo-controlled study of atomoxetine for freezing of gait in Parkinson's disease. Movement Disorders, 23 (Suppl 1), S291
• Adam, OR, Ferrara, JM, Aguilar Tabora, LG, Nashatizadeh, MM, Negoita, M, Jankovic, J. 2009. Education research: patient telephone calls in a movement disorders center: lessons in physician-trainee education. Neurology, 73 (10), e50-52
• Nashatizadeh, MM, Lyons, KE, Pahwa, R. 2009. Ropinirole prolonged release in Parkinson's disease. Clinical Interventions in Aging, 4 (1), 179-186
• Nashatizadeh, MM, Lyons, KE, Pahwa, R, Verhagen, L, Kompoliti, K. 2010. Rest Tremor
• Nashatizadeh, MM, Lyons, KE, Pahwa, R, Verhagen, L, Kompoliti, K. 2010. Postural Tremor
• Swerdlow, RH, Lyons, KE, Khosla, SW, Nashatizadeh, M, Pahwa, R. 2016. A pilot study of oxaloacetate 100 mg capsules in Parkinson's disease patients. Journal of Parkinson's Disease and Alzheimer's Disease, 3 (2), 4-7
• Lynch, S, Baker, S, Nashatizadeh, M, Thuringer, A. 2020. Disability measurement in Multiple Sclerosis patients 55 years and older: What is the Expanded Disability Status Scale really telling clinicians?. Mult Scler Relate Disord, 49 (2020 Dec 28;49:102724. doi: 10.1016/j.msard.2020. Online ahead of print.), doi: 10.1016/j.msard.2020.102724. . https://mt8fd2he2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:33609959